Findings reveal risk stratification and real-time treatment adaptation in nasopharyngeal carcinoma, indicating biomarker integration enhances personalized oncology.
EBV DNA is evolving from a static biomarker into an operational tool for precision oncology in NPC. Its integration enables biologically informed risk stratification, dynamic response assessment, and adaptive treatment strategies, with important implications for personalized management of NPC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: